Galilee Clinical Bio Research (CBR) empowers the development, approval, commercialization, and monitoring of safe, effective drugs, pharmaceutical products, medical devices, food supplements, and functional and medical food throughout Israel, Europe, USA, LATAM, and Australia.
Galilee CBR is a multi-faceted entrepreneurial center that provides, amongst others, outstanding clinical studies management services for drugs, medical devices, food supplements, plus functional and medical food.
We accompany and advise our clients through preclinical and clinical programs, from conception until receiving final regulatory approval.
Galilee CBR works in eight hospitals and many community clinics based in Galilee, which includes 2000 hospital beds and 1.5 million potential subjects for clinical studies. We undertake Pre-clinical and clinical testing in the laboratories of these hospitals and the Bar-Ilan University Faculty of Medicine in Safed.
In 2013 Dr. Lisovoder and Prof. Shalit have developed and built the GBRA- Galilee Biomedical Research Administrations.
The GBRA is a huge and prestigious government project, funded by the Ministry for Development of the Negev and Galilee. It was designed to promote biomedical research in the different Galilee medical centers and is successfully managed by Galilee CBR to date.